Market cap
$30.7m
End-of-day close multiplied by current shares on issue.
BLT · NZX
BLIS Technologies is an NZX-listed healthcare / biotechnology company. Its latest covered result is FY26, with HY23 - FY26 of source-backed result history on Annolyse.
Latest result
FY26, released 21 May 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $14.7m | ↑ +16.0% |
| NPAT | $0.7m | ↓ -16.5% |
| Operating cash flow | -$0.6m | ↓ -133.2% |
| Net debt | -$4m | — |
| ROE % | 5.3% | ↓ -1.5pp |
| Annual payout ratio vs EPS % | n/m | — |
| PBT | $0.8m | ↓ -10.2% |
| FCF pre-lease | -$1.1m | ↓ -183.4% |
| Debtor days | 51 | ↑ +65.6% |
| Inventory days | 40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days. | ↑ +88.6% |
Source: latest published briefing (FY26, released 21 May 2026). Change compares against the prior equivalent period: FY25, released 22 May 2025.
Valuation
Trailing P/E, EV/EBITDA, price-to-book and price-to-free-cash-flow ratios combine the latest available close with filing data. They are comparative measures, not forecasts or recommendations.
The latest close and share count context for the market price.
Market cap
$30.7m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
43.86x
Recent market cap compared with trailing earnings.
EPS
0.00
Recent filing-derived earnings per share.
PEG
Not available
Not meaningful without positive comparable earnings growth.
EV/EBITDA
Not available
Not available for this company right now.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
2.35x
Market value compared with latest reported equity.
Yield and investment-company valuation where supported.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Daily closes use the full available width, with hover and touch values for each observation. Expand the chart to see more detail.
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.
Chat
Ask follow-up questions about BLIS Technologies's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Financial history
The latest period is shown first.
| Metric | FY2612 MONTHS21 May 2026 | HY266 MONTHS27 November 2025 | FY2512 MONTHS22 May 2025 | HY256 MONTHS26 November 2024 | FY2412 MONTHS24 May 2024 | HY246 MONTHS16 November 2023 | FY2312 MONTHS25 May 2023 | HY236 MONTHS10 November 2022 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.7m | $7.7m | $12.6m | $6m | $11.5m | $4.8m | $10.2m | $4.3m | Chart |
| Revenue growth % | 16.0%Outside range high revenue growth. 16%; 3-period range 9.7% to 14.2%. Revenue growth: 16.0%, above normal range; 3-period mean 12.2%, range 9.7%-14.2%. | 28.1%Outside range high revenue growth. 28.1%; 3-period range 10.2% to 25.4%. Revenue growth: 28.1%, above normal range; 3-period mean 15.7%, range 10.2%-25.4%. | 9.7% | 25.4% | 12.6% | 11.4% | 14.2% | 10.2% | Chart
|
| EBITDA | — | $0.5m | $1m | — | $0.8m | — | — | — | Chart |
| EBITDA margin % | — | 6.5% | 7.9% | — | 6.9% | — | — | — | Chart |
| PBT | $0.8m | $0.44m | $0.89m | $0.2m | $0.7m | -$0.7m | -$1.3m | -$1.7m | Chart |
| PBT growth % | -11.1% | 78.3% | 28.0% | — | — | — | — | — | Chart |
| NPAT | $0.7m | $0.42m | $0.84m | $0.2m | $0.6m | -$0.7m | -$1.3m | -$1.7m | Chart |
| NPAT growth % | -12.5% | 83.0% | 29.7% | — | — | — | — | — | Chart |
| Operating cash flow | -$0.6m | -$0.49m | $1.8m | $0.74m | $1.1m | -$0.04m | $0.11m | $0.35m | Chart |
| OCF / EBITDA % | — | -97.4% | 178.5% | — | 132.0% | — | — | — | Chart |
| FCF pre-lease | -$1.1m | -$0.8m | $1.3m | $0.64m | $0.49m | -$0.12m | $0.06m | $0.31m | Chart |
| Annual payout ratio vs EPS % | n/m | — | — | — | n/m | — | — | — | Chart |
| ROE % | 5.3% | 3.3% | 6.8% | 2.0% | 5.6% | -6.6% | -12.5% | -16.1% | Chart |
| Net debt | -$4m | — | — | — | — | -$3.9m | -$4.3m | -$8.7m | Chart |
| Debtor days | 51 | — | 31 | 32 | 41 | 38 | 52 | 22 | Chart |
| Inventory days | 40Outside range high inventory days. 40d; 3-period range 21d to 26d. Inventory days: 39.6 days, above normal range; 3-period mean 23.3 days, range 21.0 days-26.2 days. | 46 | 21 | 25 | 23 | 31 | 26 | 32 | Chart
|
| Total assets | $15m | $14.8m | $14.3m | $13.4m | $12.9m | $12m | $12.8m | $12.4m | Chart |
Reference: annolyse.ai/companies/blt
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional filing-backed metrics for this company. Each point links to the relevant published briefing.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
Previous analysisHY26Result releasedAnnolyse analysis published
From BLIS grows half-year profit while operating cash turns negative
Management anticipated FY26 revenue growth of10%–15% on FY25. The chair and CEO report describes rounded half-year EBITDA of NZ$0.5m, up NZ$0.2m, and underlying half-year EBITDA of NZ$1.3m excluding one-off costs. The latter is management’s adjusted half-year measure, not an annual run-rate or a new full-year earnings forecast. Management also estimated NZ$0.1m of further supply-chain costs remained to be released.
Open questions
Primary issuer documents used for the FY26 briefing. Document labels are preserved from the publication record; Annolyse does not relabel every financial report as an annual report.
BLIS Annual Report 2026
FY26 / financial reportFinancial Results Announcement
FY26 / results announcementFinancial Results Announcement
FY26 / results releaseBLIS Annual Report 2025
FY25 / financial reportFinancial Results Announcement
FY25 / results announcementRevenue and earnings growth
FY25 / results releaseFinancial Results Announcement
HY26 / results announcementHalf Year Report 30 September 2025
HY26 / financial reportStrong revenue and underlying earnings growth
HY26 / results releaseBLIS ASM 2025 Presentation slides
HY26 / commentaryPeer context
These companies share a broad sector but may not be direct peers. Compare them only where the underlying measures are genuinely comparable.
Archive
The full chronological archive contains every published result briefing.
FY26 · Released 21 May 2026
A NZ$1.8m working-capital build—versus a historical average release of NZ$0.2m—consumed all reported profit and then some, turning free cash flow
HY26 · Released 27 November 2025
Cash investment includes property, plant, equipment and intangible purchases; comparisons retain the source statement periods.
FY25 · Released 22 May 2025
Cash investment includes property, plant, equipment and intangible purchases; comparisons retain the source statement periods.
HY25 · Released 26 November 2024
HY25 swung from a NZ$0.7m loss to a NZ$0.2m profit, but the prior year's heavy second-half skew sets a demanding bar for FY25.
FY24 · Released 24 May 2024
PBT was $0.7m and NPAT was $0.6m, each following a prior $1.3m loss.
HY24 · Released 16 November 2023
Revenue grew 11.4% yet receivables almost doubled and debtor days hit 37.9, well above the historical mean of 28.7.
Get the next BLIS Technologies result briefing and five-year history updates by email.